Effects of 3-quinuclidinyl Benzilate on Fixed-ratio Responding and Open Field Behavior in the Rat

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1983 Jan 1

PMID 6408662

Citations 1

Authors

W F Liu

N W Hu

T F Chien

J M Beaton

Affiliations

Soon will be listed here.

Abstract

The effects of 3-quinuclidinyl benzilate (QNB) in the rat were evaluated on a fixed-ratio (FR) schedule of water reinforcement and on open field behavior in a novel environment. QNB had a biphasic effect on FR-20 responding: at a low dose (0.01 mg/kg SC) it increased, and at moderate to higher doses (0.05-1.0 mg/kg SC) it decreased bar pressing in a dose-dependent manner. The effect of QNB on the multiple indices of open field activity showed that at the low dose (0.01 mg/kg SC) it depressed spontaneous motor activity (SMA), while at higher doses (0.5 and 1.0 mg/kg SC) it enhanced SMA: rearing and forelimb flicks were unaffected at low doses and increased at higher doses. In general, QNB appears to produce differential effects on operant responding and open field activity.

Citing Articles

Biphasic effects of 3-quinuclidinyl benzilate on spontaneous motor activity in mice.

Liu W, Hu N, Beaton J Psychopharmacology (Berl). 1984; 84(4):486-8.

PMID: 6441949 DOI: 10.1007/BF00431454.

References

Corne S, PICKERING R . A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967; 11(1):65-78. DOI: 10.1007/BF00401509. View

MILLER N . Effects of drugs on motivation; the value of using a variety of measures. Ann N Y Acad Sci. 1956; 65(4):318-33. DOI: 10.1111/j.1749-6632.1956.tb49642.x. View

BIEL J, NUHFER P, HOYA W, LEISER H, Abood L . Cholinergic blockade as an approach to the development of new psychotropic agents. Ann N Y Acad Sci. 1962; 96:251-62. DOI: 10.1111/j.1749-6632.1962.tb50120.x. View

Snyder S, Chang K, Kuhar M, Yamamura H . Biochemical indentification of the mammalian muscarinic cholinergic receptor. Fed Proc. 1975; 34(10):1915-21. View

Cross A, Waddington J . [3H] Quinuclidinyl benzylate and [3H] GABA receptor binding in rat substantia nigra after 6-hydroxy-dopamine lesions. Neurosci Lett. 1980; 17(3):271-5. DOI: 10.1016/0304-3940(80)90035-x. View

KOSMAN M . EFFECT OF AMPHETAMINE ON THE LEARNING AND PERFORMANCE OF MICE IN A SWIMMING MAZE. Proc Soc Exp Biol Med. 1964; 115:728-31. DOI: 10.3181/00379727-115-29021. View

Meyerhoffer A . Absolute configuration of 3-quinuclidinyl benzilate and the behavioral effect in the dog of the optical isomers. J Med Chem. 1972; 15(9):994-5. DOI: 10.1021/jm00279a030. View

Dews P . Modification by drugs of performance on simple schedules of positive reinforcement. Ann N Y Acad Sci. 1956; 65(4):268-81. DOI: 10.1111/j.1749-6632.1956.tb49639.x. View

Silva M, Calil H . Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia. 1975; 42(2):163-71. DOI: 10.1007/BF00429548. View

10.

OSTFELD A, VISOTSKY H, ABOOD L, LEBOVITZ B . Studies with a new hallucinogen; some dosage-response data for JB 318. AMA Arch Neurol Psychiatry. 1959; 81(2):256-63. View

11.

Yamamura H, Snyder S . Muscarinic cholinergic binding in rat brain. Proc Natl Acad Sci U S A. 1974; 71(5):1725-9. PMC: 388311. DOI: 10.1073/pnas.71.5.1725. View

12.

Heiser J, Gillin J . The reversal of anticholinergic drug-induced delirium and coma with physostigmine. Am J Psychiatry. 1971; 127(8):1050-4. DOI: 10.1176/ajp.127.8.1050. View

13.

ALBANUS L . Central and peripheral effects of anticholinergic compounds. Acta Pharmacol Toxicol (Copenh). 1970; 28(4):305-26. DOI: 10.1111/j.1600-0773.1970.tb00557.x. View

14.

Duvoisin R, Katz R . Reversal of central anticholinergic syndrome in man by physostigmine. JAMA. 1968; 206(9):1963-5. View

15.

BAUMGOLD J, Abood L, Aronstam R . Studies on the relationship of binding affinity to psychoactive and anticholingergic potency of a group of psychotomimetic glycolates. Brain Res. 1977; 124(2):331-40. DOI: 10.1016/0006-8993(77)90889-7. View

16.

Gershon S . Behavioral effects of anticholinergic psychotomimetics and their antagonists in man and animals. Panel discussion. Recent Adv Biol Psychiatry. 1965; 8:141-9. DOI: 10.1007/978-1-4899-7313-9_20. View

17.

Ketchum J, Sidell F, CROWELL Jr E, Aghajanian G, HAYES Jr A . Atropine, scopolamine, and ditran: comparative pharmacology and antagonists in man. Psychopharmacologia. 1973; 28(2):121-45. DOI: 10.1007/BF00421398. View

18.

Marshall E . Scientologists Obtain Potent Hallucinogen, QNB. Science. 1979; 205(4410):982-3. DOI: 10.1126/science.205.4410.982-a. View

19.

Sloviter R, Drust E, Connor J . Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther. 1978; 206(2):339-47. View

20.

Davis H, FORD H, Tupin J, Colvin A . CLINICAL EVALUATION OF JB-329 (DITRAN). Dis Nerv Syst. 1964; 25:179-83. View